Results 101 to 110 of about 8,360 (233)

Langerin+CD8+ Dendritic Cells in the Splenic Marginal Zone: Not So Marginal After All

open access: yesFrontiers in Immunology, 2019
Dendritic cells (DC) fulfill an essential sentinel function within the immune system, acting at the interface of innate and adaptive immunity. The DC family, both in mouse and man, shows high functional heterogeneity in order to orchestrate immune ...
Ronald A. Backer   +2 more
doaj   +1 more source

Calcitonin gene-related peptide inhibits Langerhans cell-mediated HIV-1 transmission. [PDF]

open access: yes, 2013
International audienceUpon its mucosal entry, human immunodeficiency virus type 1 (HIV-1) is internalized by Langerhans cells (LCs) in stratified epithelia and transferred locally to T cells.
Ahmed   +37 more
core   +4 more sources

Glycans and Chirality: Stereoselectivity at the Core of DC‐SIGN's Recognition. A Novel View of the Optimum Minimal Ligand Epitope

open access: yesChemistry – A European Journal, Volume 31, Issue 37, July 2, 2025.
The stereochemical diversity of the “glycan code” enables similar chiral motifs to arise from both D‐ and L‐sugars. Focused on DC‐SIGN–glycan recognition, two diverse monosaccharide scaffolds, D‐Man (D‐Rha) and L‐Gal (L‐Fuc), maintain the exquisite stereochemistry encoded in the minimal binding epitope.
J. Daniel Martínez   +7 more
wiley   +1 more source

Langerin (CD207) represents a novel interferon-stimulated gene in Langerhans cells [PDF]

open access: yesCellular & Molecular Immunology, 2019
Interferons (IFNs) are “warning signal” cytokines released upon pathogen sensing. IFNs control the expression of interferon-stimulated genes (ISGs), which are often crucial to restrict viral infections and establish a cellular antiviral state.1,2 Langerin (CD207), a well-known surface receptor on Langerhans cells (LC), belongs to the C-type lectin ...
Matthew Owen Ivory   +11 more
openaire   +3 more sources

Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.

open access: yesPLoS ONE, 2011
Transfer of antigen between antigen-presenting cells (APCs) is potentially a physiologically relevant mechanism to spread antigen to cells with specialized stimulatory functions.
Troels R Petersen   +4 more
doaj   +1 more source

Diffuse plane xanthomas as the first manifestation of multiple myeloma

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Eleni Koutra   +5 more
wiley   +1 more source

Leveraging current insights on IL‐10‐producing dendritic cells for developing effective immunotherapeutic approaches

open access: yesFEBS Letters, Volume 599, Issue 14, Page 2025-2047, July 2025.
In vivo IL‐10 produced by tissue‐resident tolDC is involved in maintaining/inducing tolerance. Depending on the agent used for ex vivo tolDC generation, cells acquire common features but prime T cells towards anergy, FOXP3+ Tregs, or Tr1 cells according to the levels of IL‐10 produced. Ex vivo‐induced tolDC were administered to patients to re‐establish/
Konstantina Morali   +3 more
wiley   +1 more source

Editorial: Faux amis: Langerin-expressing DC in humans and mice [PDF]

open access: yesJournal of Leukocyte Biology, 2015
Discussion on the identification of Langerin+ DC populations in humans.
openaire   +3 more sources

Duality of β-glucan microparticles: antigen carrier and immunostimulants [PDF]

open access: yes, 2016
Designing efficient recombinant mucosal vaccines against enteric diseases is still a major challenge. Mucosal delivery of recombinant vaccines requires encapsulation in potent immunostimulatory particles to induce an efficient immune response. This paper
Baert, Kim   +4 more
core   +2 more sources

JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025

open access: yesJournal of Cellular and Molecular Medicine, Volume 29, Issue 13, July 2025.
ABSTRACT Advances in biotechnology are set to revolutionise the treatment of haematological malignancies. Current treatments have limited efficacy due to their high toxicity and poor long‐term outcomes, particularly in acute myeloid leukaemia (AML). In 2024–2025, emerging targeted therapies promise improved results with reduced adverse effects.
Akbar M. Shahid   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy